IFNAR2 Decoy Receptor Targeting to Reduce IFN Therapy Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing IFN signaling therapies face challenges with off-target toxicity and acquired cellular resistance, necessitating new methods for less toxic and more effective control of cellular sensitivity to IFN signaling.
Innovation Solution
Modulating the expression of IFNAR2 isoforms, particularly IFNAR2-L and IFNAR2-S, through techniques like CRISPR/Cas9-mediated deletion, siRNA, and overexpression to manipulate the ratio of these isoforms, thereby controlling IFN signaling and innate immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IFN signaling is enhanced to treat cancer and viral infections, then therapeutic efficacy is improved, but off-target toxicity increases
Solution Approach 1:
The patent applies local quality by creating isoform-specific modulation strategies. Instead of uniformly enhancing all IFNAR2 receptors, the invention selectively targets IFNAR2-L (full-length signaling receptor) while sparing IFNAR2-S (truncated decoy receptor). This localized differentiation allows therapeutic IFN signaling enhancement through IFNAR2-L while avoiding toxic effects that would result from non-specific IFNAR2 modulation, thereby resolving the contradiction between efficacy and toxicity.
Solution Approach 2:
The patent segments the IFNAR2 receptor into two distinct functional isoforms: IFNAR2-L with complete signaling capability and IFNAR2-S with decoy function. By developing isoform-specific modulation approaches, the invention enables selective enhancement of therapeutic IFN signaling through IFNAR2-L without triggering the toxic effects associated with non-specific IFNAR2 activation. This segmentation allows differential control of beneficial versus harmful IFN signaling effects.
2Reliability
If IFN signaling is continuously activated to maintain immune response, then antiviral protection is improved, but acquired cellular resistance develops
Solution Approach 1:
The patent applies dynamics by enabling flexible, reversible modulation of IFNAR2-L expression levels rather than permanent genetic modification. The use of CRISPR/Cas9-mediated deletion creates a controllable system where IFNAR2-L can be selectively reduced in specific cell types or conditions, allowing dynamic adjustment of IFN sensitivity. This dynamic control prevents the system from becoming static and resistant, maintaining cellular responsiveness to IFN therapy over time.
Solution Approach 2:
The patent applies local quality by implementing isoform-specific modulation that selectively affects IFNAR2-L while preserving IFNAR2-S. This creates localized differences in IFN signaling capacity across different cell types or tissue compartments. By maintaining heterogeneity in IFN sensitivity through selective IFNAR2-L modulation rather than uniform cellular resistance, the system prevents widespread acquired resistance while maintaining antiviral protection where needed.
3Reliability
If IFNAR2-L expression is increased to enhance IFN signaling, then sensitivity to IFN is improved, but toxicity increases
Solution Approach 1:
The patent applies local quality by developing isoform-specific strategies that selectively modulate IFNAR2-L expression. Rather than globally increasing all IFNAR2 receptors (which would include the protective IFNAR2-S decoy), the invention uses CRISPR/Cas9 to precisely control IFNAR2-L levels in specific cell types or tissues. This localized IFNAR2-L enhancement improves IFN sensitivity and therapeutic efficacy while avoiding the toxic effects that would result from uncontrolled systemic IFNAR2 activation.
Data Source
AI summary
The present invention includes systems, methods and compositions to modulate the IFN signaling pathway and its downstream effects on the innate immune response by regulating the expression of one or more IFNAR2 isoforms. In a preferred aspect, the modulation of the IFN signaling pathway may be accomplished by modulating the relative ration between IFNAR2 isoforms, IFNAR2-L and IFNAR2-S.